Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era

World J Gastroenterol. 2024 Feb 28;30(8):806-810. doi: 10.3748/wjg.v30.i8.806.ABSTRACTApproximately 50%-70% of patients with hepatocellular carcinoma experience recurrence within five years after curative hepatic resection or ablation. As a result, many patients receive adjuvant therapy after curative resection or ablation in order to prolong recurrence-free survival. The therapy recommended by national guidelines can differ, and guidelines do not specify when to initiate adjuvant therapy or how long to continue it. These and other unanswered questions around adjuvant therapies make it difficult to optimize them and determine which may be more appropriate for a given type of patient. These questions need to be addressed by clinicians and researchers.PMID:38516235 | PMC:PMC10950644 | DOI:10.3748/wjg.v30.i8.806
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Source Type: research